These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
450 related items for PubMed ID: 9423834
1. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Melby PC, Yang YZ, Cheng J, Zhao W. Infect Immun; 1998 Jan; 66(1):18-27. PubMed ID: 9423834 [Abstract] [Full Text] [Related]
2. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10. Bhaumik SK, Naskar K, De T. Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771 [Abstract] [Full Text] [Related]
3. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani. Rostan O, Gangneux JP, Piquet-Pellorce C, Manuel C, McKenzie AN, Guiguen C, Samson M, Robert-Gangneux F. mBio; 2013 Sep 17; 4(5):e00383-13. PubMed ID: 24045639 [Abstract] [Full Text] [Related]
4. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. Melby PC, Chandrasekar B, Zhao W, Coe JE. J Immunol; 2001 Feb 01; 166(3):1912-20. PubMed ID: 11160239 [Abstract] [Full Text] [Related]
5. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. J Immunol; 2005 Jun 01; 174(11):7160-71. PubMed ID: 15905560 [Abstract] [Full Text] [Related]
6. Infection pattern and immune response in the spleen and liver of BALB/c mice intracardially infected with Leishmania donovani amastigotes. Mukherjee P, Ghosh AK, Ghose AC. Immunol Lett; 2003 Apr 03; 86(2):131-8. PubMed ID: 12644314 [Abstract] [Full Text] [Related]
7. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. Lehmann J, Enssle KH, Lehmann I, Emmendörfer A, Lohmann-Matthes ML. J Interferon Cytokine Res; 2000 Jan 03; 20(1):63-77. PubMed ID: 10670653 [Abstract] [Full Text] [Related]
8. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A. J Immunol; 2011 Dec 15; 187(12):6417-27. PubMed ID: 22079980 [Abstract] [Full Text] [Related]
9. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Satoskar A, Bluethmann H, Alexander J. Infect Immun; 1995 Dec 15; 63(12):4894-9. PubMed ID: 7591152 [Abstract] [Full Text] [Related]
10. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. Stäger S, Smith DF, Kaye PM. J Immunol; 2000 Dec 15; 165(12):7064-71. PubMed ID: 11120835 [Abstract] [Full Text] [Related]
11. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Engwerda CR, Murphy ML, Cotterell SE, Smelt SC, Kaye PM. Eur J Immunol; 1998 Feb 15; 28(2):669-80. PubMed ID: 9521077 [Abstract] [Full Text] [Related]
12. Modulation of CD11C+ splenic dendritic cell functions in murine visceral leishmaniasis: correlation with parasite replication in the spleen. Basu A, Chakrabarti G, Saha A, Bandyopadhyay S. Immunology; 2000 Feb 15; 99(2):305-13. PubMed ID: 10692051 [Abstract] [Full Text] [Related]
13. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. Scott P. J Immunol; 1991 Nov 01; 147(9):3149-55. PubMed ID: 1833466 [Abstract] [Full Text] [Related]
14. Sex-determined susceptibility and differential IFN-gamma and TNF-alpha mRNA expression in DBA/2 mice infected with Leishmania mexicana. Satoskar A, Alexander J. Immunology; 1995 Jan 01; 84(1):1-4. PubMed ID: 7890293 [Abstract] [Full Text] [Related]
15. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Mazumdar T, Anam K, Ali N. Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644 [Abstract] [Full Text] [Related]
16. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Bhowmick S, Ravindran R, Ali N. Infect Immun; 2008 Mar 12; 76(3):1003-15. PubMed ID: 18195029 [Abstract] [Full Text] [Related]
17. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F. Eur J Immunol; 2000 Oct 12; 30(10):2935-43. PubMed ID: 11069076 [Abstract] [Full Text] [Related]
18. Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection. Melby PC, Tabares A, Restrepo BI, Cardona AE, McGuff HS, Teale JM. Exp Parasitol; 2001 Sep 12; 99(1):17-25. PubMed ID: 11708830 [Abstract] [Full Text] [Related]
19. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Infect Immun; 2001 Aug 12; 69(8):4719-25. PubMed ID: 11447143 [Abstract] [Full Text] [Related]
20. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice. Dey R, Majumder N, Bhattacharyya Majumdar S, Bhattacharjee S, Banerjee S, Roy S, Majumdar S. Scand J Immunol; 2007 Dec 12; 66(6):671-83. PubMed ID: 18021365 [Abstract] [Full Text] [Related] Page: [Next] [New Search]